Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 879Leukemia, Lymphocytic, Chronic, B-Cell 560Leukemia 426Hematologic Neoplasms 332Precursor Cell Lymphoblastic Leukemia-Lymphoma 331Myelodysplastic Syndromes 302Leukemia, Myelogenous, Chronic, BCR-ABL Positive 244Lymphoma, Non-Hodgkin 224Recurrence 222Lymphoma 196Neoplasms 195Multiple Myeloma 129Lymphoma, Mantle-Cell 119Lymphoma, Large B-Cell, Diffuse 114Lymphoma, Follicular 114Leukemia, Myelomonocytic, Chronic 89Lymphoma, B-Cell 88Lymphoma, B-Cell, Marginal Zone 85Leukemia, B-Cell 79Burkitt Lymphoma 64Leukemia, Myeloid, Chronic-Phase 57Waldenstrom Macroglobulinemia 56Leukemia, Myeloid 53Hodgkin Disease 47Hematologic Diseases 47Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 45Myeloproliferative Disorders 40Primary Myelofibrosis 39Bronchiolitis Obliterans Syndrome 35Anemia, Refractory, with Excess of Blasts 32

Interventions

bosutinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Translocation, Genetic × Other hematologic neoplasm × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡